Pharmaceuticals Analysts discuss novel treatments and clinical trial design innovations in focal onset epilepsy (RAPP, XENE, NPCE) on an Analyst/Industry conference call to be held on July 10.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP:
- Rapport Therapeutics files to sell 470,589 shares of common stock for holders
- Rapport Therapeutics files $400M mixed securities shelf
- Rapport Therapeutics Elects New Directors at Annual Meeting
- Rapport Therapeutics management to meet with Citizens JMP
- Rapport Therapeutics Completes Enrollment for Phase 2a Trial